Cancer biomarker HER-2/neu in breast cancer in Indian women

Código QR

Cancer biomarker HER-2/neu in breast cancer in Indian women

Rajeev Singhai1, Amit V Patil2, Vinayak W Patil11Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, IndiaAim and objectives: In Indian women with breast cancer, the HER-2/neu...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Singhai R, Patil VW, Patil AV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a17f1623757842ac95bcb9d9af75bb38
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
por: Vinayak W Patil, et al.
Publicado: (2011)

Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
por: Patil AV, et al.
Publicado: (2011)

The p53 breast cancer tissue biomarker in Indian women
por: Patil V, et al.
Publicado: (2011)

Utility of Serum HER-2/ neu in Prediction of Tissue HER-2 /neu Status of Primary Breast Cancer
por: Maral Mokhtari, et al.
Publicado: (2021)

Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
por: Matthew M Seavey, et al.
Publicado: (2009)

Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
por: Advani P, et al.
Publicado: (2015)

Role of pertuzumab in the treatment of HER2-positive breast cancer
por: Hubalek M, et al.
Publicado: (2012)

New developments in the treatment of HER2-positive breast cancer
por: Nahta R
Publicado: (2012)

Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
por: Stenehjem DD, et al.
Publicado: (2014)

Triple negative breast cancer: an Indian perspective
por: Akhtar M, et al.
Publicado: (2015)

Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014)

Potential of afatinib in the treatment of patients with HER2-positive breast cancer
por: Geuna E, et al.
Publicado: (2012)

The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
por: Moya-Horno I, et al.
Publicado: (2015)

HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now
por: Ilana Schlam, et al.
Publicado: (2021)

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
por: Hurvitz SA, et al.
Publicado: (2012)

Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer
por: G. Griguolo, et al.
Publicado: (2021)

Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014)

Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
por: Gaia Griguolo, et al.
Publicado: (2021)

Author Correction: Evolution of HER2-low expression from primary to recurrent breast cancer
por: Federica Miglietta, et al.
Publicado: (2021)

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
por: Francesco Schettini, et al.
Publicado: (2021)

The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers
por: Leticia De Mattos-Arruda, et al.
Publicado: (2021)

Tamoxifen for women at high risk of breast cancer
por: Nazarali SA, et al.
Publicado: (2014)

De-escalation of radiation therapy in patients with stage I, node-negative, HER2-positive breast cancer
por: Jose G. Bazan, et al.
Publicado: (2021)

The obesity paradox in early and advanced HER2 positive breast cancer: pooled analysis of clinical trial data
por: Natansh D. Modi, et al.
Publicado: (2021)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021)

Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
por: Xavier Pivot, et al.
Publicado: (2017)

Critical analysis of the potential for microRNA biomarkers in breast cancer management
por: Graveel CR, et al.
Publicado: (2015)

Phase 1b clinical trial of ado-trastuzumab emtansine and ribociclib for HER2-positive metastatic breast cancer
por: Laura M. Spring, et al.
Publicado: (2021)

Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer
por: Hanne Vos, et al.
Publicado: (2021)

Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
por: Merriam PA, et al.
Publicado: (2011)

Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer
por: Corey Speers, et al.
Publicado: (2017)

Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
por: Lower EE, et al.
Publicado: (2017)

Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
por: Veronica Giusti, et al.
Publicado: (2021)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
por: Salkeni MA, et al.
Publicado: (2021)

Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab
por: Lize Wang, et al.
Publicado: (2021)

Management of early breast cancer in older women: from screening to treatment
por: Elomrani F, et al.
Publicado: (2015)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Nina Radosevic-Robin, et al.
Publicado: (2021)

Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
por: Vogel VG
Publicado: (2011)

Allostatic load: a framework to understand breast cancer outcomes in Black women
por: Samilia Obeng-Gyasi, et al.
Publicado: (2021)

Inherited predisposition to breast cancer in the Carolina Breast Cancer Study
por: Tom Walsh, et al.
Publicado: (2021)